Sawai Pharmaceutical Co. Ltd.

Sawai Pharmaceutical is a pharmaceutical company. Along with its subsidiaries Co. is engaged in the research development, manufacture and sale of ethical drugs and proprietary drugs. Co. provides cardiovascular drugs, gastro-intestinal drugs, blood/body fluid pharmaceutical products, other metabolic drugs, central nervous system drugs, antibiotics drugs, urogenital and anal organ agents, antiallergic drugs, chemotherapeutic drugs, and others. Co. is also engaged in the distribution of its products through sales companies, wholesale shops and other pharmaceutical manufacturers, among others.
  • Ticker4555
  • ISINJP3323050009
  • SectorPharmaceuticals & Biotechnology
  • CountryJapan

Analysts

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior

SAWAI PHARM.CO.LTD. sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of SAWAI PHARM.CO.LTD. (JP), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date October 25, 2019, the closing price was JPY 6,020.00 and its potential was estimated at JPY 6,436.26.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior